Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
Expert Opin Drug Deliv
; 2(5): 891-908, 2005 Sep.
Article
en En
| MEDLINE
| ID: mdl-16296785
ABSTRACT
Ophthalmic drugs typically achieve < 10% ocular bioavailability. A drug applied to the surface of the eye may cross ocular-blood barriers where it may encounter metabolising enzymes and cellular transporters before it distributes to the site of action. Characterisation of ocular enzyme systems and cellular transporters and their respective substrate selectivity have provided new insight into the roles these proteins may play in ocular drug delivery and distribution. Altered metabolism and transport have been proposed to contribute to a number of ocular disease processes including inflammation, glaucoma, cataract, dry eye and neurodegeneration. As ocular enzyme and transport systems are better characterised, their properties become an integral consideration in drug design and development.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Soluciones Oftálmicas
/
Sistemas de Liberación de Medicamentos
/
Ojo
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Drug Deliv
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos